PD-L1 expression in nonclear-cell renal cell carcinoma

T. K. Choueiri, A. P. Fay, K. P. Gray, M. Callea, Thai H Ho, L. Albiges, J. Bellmunt, J. Song, I. Carvo, M. Lampron, M. L. Stanton, F. S. Hodi, D. F. McDermott, M. B. Atkins, G. J. Freeman, M. S. Hirsch, S. Signoretti

Research output: Contribution to journalArticle

165 Scopus citations

Abstract

Background: Programmed death ligand-1 (PD-L1) expression in nonclear-cell RCC (non-ccRCC) and its association with clinical outcomes are unknown. Methods: Formalin-fixed paraffin-embedded (FFPE) specimens were obtained from 101 patients with non-ccRCC. PD-L1 expression was evaluated by immunohistochemistry in both tumor cell membrane and tumor-infiltrating mononuclear cells (TIMC). PD-L1 tumor positivity was defined as ≥5% tumor cell membrane staining. For PD-L1 expression in TIMC, a combined score based on the extent of infiltrate and percentage of positive cells was used. Baseline clinico-pathological characteristics and outcome data [time to recurrence (TTR) and overall survival (OS)] were correlated with PD-L1 staining. Results: Among 101 patients, 11 (10.9%) were considered PD-L1+ in tumor cells: 2/36 (5.6%) of chromophobe RCC, 5/50 (10%) of papillary RCC, 3/10 (30%) of Xp11.2 translocation RCC and 1/5 (20%) of collecting duct carcinoma. PD-L1 positivity (PD-L1+) in tumor cells was significantly associated with higher stage (P =0.01) and grade (P= 0.03), as well as shorter OS (P < 0.001). On the other hand, PD-L1 positivity by TIMC was observed in 57 (56.4%) patients: 13/36 (36.1%) of chromophobe RCC, 30/50 (60%) of papillary RCC, 9/10 (90%) of Xp11.2 translocation RCC and 5/5 (100%) of collecting duct carcinoma. A trend toward shorter OS was observed in patients with PD-L1+ in TIMC (P = 0.08). PD-L1+ in both tumor cell membrane and TIMC cells were associated with shorter TTR (P =0.02 and P=0.03, respectively). Conclusion: In non-ccRCC, patients with PD-L1+ tumors appear to have worse clinical outcomes, although only PD-L1 positivity in tumor cells is associated with higher tumor stage and grade.

Original languageEnglish (US)
Pages (from-to)2178-2184
Number of pages7
JournalAnnals of Oncology
Volume25
Issue number11
DOIs
StatePublished - Nov 1 2014

Keywords

  • Benign kidney tumors
  • Immunotherapy
  • Nonclear-cell renal cell carcinoma
  • PD-1 inhibitors
  • PD-L1
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Medicine(all)
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'PD-L1 expression in nonclear-cell renal cell carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Choueiri, T. K., Fay, A. P., Gray, K. P., Callea, M., Ho, T. H., Albiges, L., Bellmunt, J., Song, J., Carvo, I., Lampron, M., Stanton, M. L., Hodi, F. S., McDermott, D. F., Atkins, M. B., Freeman, G. J., Hirsch, M. S., & Signoretti, S. (2014). PD-L1 expression in nonclear-cell renal cell carcinoma. Annals of Oncology, 25(11), 2178-2184. https://doi.org/10.1093/annonc/mdu445